摘要
摘要
Should SABR Be Used for Oligometastatic Disease?The efficacy of stereotactic ablative radiotherapy in the oligometastatic setting has not been shown in phase 3 randomized controlled trials for breast (or many other) cancers. We review the evidence base and propose a trial to address the question, should stereotactic ablative radiotherapy be used for oligometastatic disease?
KM 提取结果
0 个 Figure · 0 个 KM 面板